Onesource Specialty Pharma Ltd.

NSE: ONESOURCE · Healthcare

₹1,599.80+1.13%06 Nov 2026

Check figures: unusual quarterly results in SEP '26 (₹82.48 cr vs a typical ₹4.60 cr). This may be a filing error (e.g. lakh filed as crore) or a genuine one-off; figures are shown as filed. Trailing-twelve-month figures include it.

Ask the data

Instant answers about Onesource Specialty Pharma Ltd. — computed from its filings, no language model

Market cap₹18,345 cr

Current price₹1,599.80

High / Low₹1,878 / ₹1,114

P/E—

P/B3.10

Book value₹516.3

ROE-0.0%

ROCE1.4%

Debt / equity0.25

Dividend yield—

EPS (TTM)₹-0.14

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY25	FY26
Revenue	1,445	1,422
EBITDA	467	304
Operating margin	32.3%	21.4%
Interest	166	122
Depreciation	274	279
Profit before tax	-67	-92
Tax	-50	-18
Net profit	-18	-74
EPS ₹	-1.63	-6.44
Operating cash flow	-22	9
Capex	0	569
Dividend paid	0	0
Total assets	7,550	8,210
Equity	5,881	5,831

Quarterly performance

last 9 quarters · ₹ crore

showing latest 8 of 9 periods

	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26*
Revenue	68	393	426	327	376	290	428	449	516
Operating profit	0	143	183	88	106	17	92	123	163
Operating margin	0.2%	36.5%	42.8%	27.0%	28.3%	6.0%	21.5%	27.5%	31.6%
Other income	1	5	3	5	3	5	2	4	1
Interest	21	46	33	27	34	38	23	31	35
Depreciation	19	69	68	68	70	70	72	72	75
Profit before tax	-39	-66	84	-4	6	-93	-0	20	53
Tax	0	2	-15	-4	-5	-4	-5	-5	-5
Net profit	0	0	98	-0	10	-89	5	0	82
EPS ₹	-18.82	-6.31	8.61	-0.02	0.92	-7.74	0.40	2.18	5.01
Revenue YoY	—	—	—	—	452.8%	-26.0%	0.5%	37.2%	37.4%
Profit YoY	—	—	—	—	—	—	-95.3%	—	687.0%

Returns & margins

trailing-twelve-month, per quarter

	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	1.7%	1.8%	0.3%	-1.3%	-1.3%	-0.0%
ROCE	1.5%	2.3%	1.8%	0.4%	0.8%	1.4%
Net margin	8.1%	7.1%	1.4%	-5.2%	-4.8%	-0.1%
EBITDA margin	34.1%	34.2%	27.8%	21.4%	22.0%	23.5%
Debt / equity	0.13	0.18	0.18	0.22	0.22	0.25
Interest coverage	0.79	1.13	0.94	0.25	0.46	0.84
Asset turnover	0.16	0.19	0.18	0.17	0.19	0.20

Balance sheet

equity vs borrowings over time · ₹ crore

	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	4	11	11	11	11
Other equity / reserves	401	5,869	5,893	5,820	5,909
Total equity	405	5,881	5,904	5,831	5,921
Borrowings	604	772	1,066	1,276	1,484
Current liabilities	414	1,114	1,331	1,442	1,664
Non-current liabilities	464	556	778	937	1,002
Total assets	1,283	7,550	8,013	8,210	8,586
Property, plant & equipment	654	897	921	926	1,188
Capital work-in-progress	43	60	173	314	141
Investments	11	16	20	16	17
Inventories	14	158	325	439	446
Receivables	63	473	664	690	1,033
Cash & equivalents	9	156	104	36	14

Cash flow

annual · ₹ crore · line = free cash flow

	FY25	FY26
Cash from operations	-22	9
Cash from investing	-201	-495
Cash from financing	1,987	359
Capex	0	569
Free cash flow	-22	-561
Dividends paid	0	0

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹1,188 cr14%

CWIP

₹141 cr2%

Investments

₹17 cr0%

Inventories

₹446 cr5%

Receivables

₹1,033 cr12%

Cash & equivalents

₹14 cr0%

Other assets

₹5,747 cr67%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Onesource Specialty Pharma Ltd.	18,345	1,599.80	—	3.10	-0.0%

StoxGud checklist: Neutral setup · 4/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+4.7%

6 months-11.9%

1 year-13.7%

3Y CAGR—

5Y CAGR—

10Y CAGR—

50-day avg₹1,525.92

200-day avg₹1,550.50

RSI (14)71

Compare Onesource Specialty Pharma Ltd. with

Granules India vs Onesource Specialty Pharma Onesource Specialty Pharma vs Caplin Point Laboratories Onesource Specialty Pharma vs Syngene International Onesource Specialty Pharma vs Cohance Lifesciences Onesource Specialty Pharma vs Poly Medicure

FAQs

What is the share price of Onesource Specialty Pharma Ltd.?

Onesource Specialty Pharma Ltd. (ONESOURCE) closed at ₹1,599.80 on NSE on 06 Nov 2026.

What is the market cap of Onesource Specialty Pharma Ltd.?

₹18,345 crore at the latest close.

How fast is Onesource Specialty Pharma Ltd. growing?

Onesource Specialty Pharma Ltd.: Latest-quarter revenue is up 37.4% year on year, profit up 687.0%.

How profitable is Onesource Specialty Pharma Ltd.?

On a trailing-twelve-month basis return on equity is -0.0%, return on capital employed 1.4%, operating margin 23.5%, net margin -0.1%.

How much debt does Onesource Specialty Pharma Ltd. have?

Onesource Specialty Pharma Ltd. is lightly geared: debt to equity is 0.25 with borrowings of ₹1,484 cr against cash of ₹14 cr (balance sheet of 2026-09-30). Operating profit covers interest 0.8 times.

Financials parsed from Onesource Specialty Pharma Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '24, annual from FY25, balance sheet from Sep '24. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.